Raltitrexed (Tomudex™) plus doxorubicin (DOX) in patients with advanced gastric cancer:: Interim results of a phase I dose escalation study

被引：0
|
作者：
Bjarnason, G [1 ]
Charpentier, D [1 ]
Winquist, E [1 ]
Wong, R [1 ]
Matthews, S [1 ]
Seymour, L [1 ]
机构：
[1] NCI, Canada Clin Trials Grp, Kingston, ON, Canada
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
459
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] NCICCTG IND 98: A phase I dose escalation study of raltitrexed (Tomudex) Plus doxorubicin (DOX) in patients with advanced cancer
    Biarnason, G
    Charpentier, D
    Wong, R
    Goel, R
    Smith, M
    Abugaber, A
    Matthews, S
    Seymour, L
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [2] 'Tomudex' (raltitrexed) plus 5FU combination treatment for patients with advanced colorectal cancer: a Phase I study
    Mayer, S
    Hilger, R
    Muller, C
    Dohmen, D
    Kloeppel, R
    Vanhoefer, U
    Scheulen, ME
    Seeber, S
    Harstick, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [3] Interim results of a phase I trial suggests that 'Tomudex' (raltitrexed) may act synergistically with 5-FU in patients with advanced colorectal cancer (CRC)
    Schwartz, GK
    Bertino, JL
    Kemeny, N
    Saltz, L
    Sugarman, A
    Kelsen, DK
    Tong, W
    Lowery, C
    Smith, M
    ANNALS OF ONCOLOGY, 1998, 9 : 36 - 36
  • [4] Raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer (NSCLC): Preliminary results of a Phase I dose-escalation study
    Manegold, C
    Buchholz, E
    Kloeppel, R
    Kreisel, C
    Smith, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S253 - S253
  • [5] A phase I/II dose-finding study of Tomudex® (raltitrexed) and cisplatin in patients with locally advanced or metastatic head and neck cancer
    Huinink, DT
    de Jong, RJB
    Verschuur, HP
    Keizer, HJ
    ANNALS OF ONCOLOGY, 1998, 9 : 78 - 78
  • [6] Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer
    Sato, A
    Kurihara, M
    Horikoshi, N
    Aiba, K
    Kikkawa, N
    Shirouzu, K
    Mitachi, Y
    Sakata, Y
    Wakui, A
    ANTI-CANCER DRUGS, 1999, 10 (08) : 741 - 748
  • [7] Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
    Chawla, Sant P.
    Staddon, Arthur
    Hendifar, Andrew
    Messam, Conrad A.
    Patwardhan, Rita
    Kamel, Yasser Mostafa
    BMC CANCER, 2013, 13
  • [8] Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
    Sant P Chawla
    Arthur Staddon
    Andrew Hendifar
    Conrad A Messam
    Rita Patwardhan
    Yasser Yasser Mostafa Kamel
    BMC Cancer, 13
  • [9] Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
    Kristeleit, Rebecca
    Moreno, Victor
    Boni, Valentina
    Guerra, Eva M.
    Kahatt, Carmen
    Romero, Ignacio
    Calvo, Emiliano
    Baste, Neus
    Lopez-Vilarino, Jose A.
    Siguero, Mariano
    Alfaro, Vicente
    Zeaiter, Ali
    Forster, Martin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (11) : 1428 - 1436
  • [10] Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens
    Blay, JY
    Judson, I
    Rodenhuis, S
    Hermans, C
    Smith, M
    van Glabbeke, M
    Verweij, J
    ANTI-CANCER DRUGS, 1999, 10 (10) : 873 - 877
12345